Midostaurin - Novartis Oncology
Alternative Names: 4-N-benzoyl staurosporine; Benzoylstaurosporine; CGP-41251; N-benzoyl-staurosporine; PKC-412; PKC-412A; RydaptLatest Information Update: 05 Aug 2024
At a glance
- Originator Novartis
- Developer Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Novartis; Novartis Oncology; Ohio State University Comprehensive Cancer Center
- Class Antineoplastics; Carbazoles; Eye disorder therapies; Indole alkaloids; Skin disorder therapies; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor alpha receptor antagonists; Platelet-derived growth factor beta receptor antagonists; Protein kinase C inhibitors; Proto-oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Registered Acute myeloid leukaemia; Systemic mastocytosis
- No development reported Rectal cancer
- Discontinued Acute biphenotypic leukaemia; Colorectal cancer; Diabetic macular oedema; Gastrointestinal stromal tumours; Multiple myeloma
Most Recent Events
- 30 Jul 2024 Cardiff University plans a phase II/III trial for Acute myeloid leukemia (In Adolescents, In Adults) in Denmark, New Zealand and United Kingdom
- 08 Jun 2023 Efficacy data from a phase II trial in Acute myeloid leukaemia presented at the 28th Congress of the European Haematology Association (EHA-2023)
- 10 Dec 2022 Pharmacodynamics and efficacy data from a phase II trial in Acute myeloid leukemia presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)